AI assistant
Virbac — Earnings Release 2009
Oct 14, 2009
1753_iss_2009-10-14_d9a184a7-18a0-4b79-96cb-7f7f82221816.pdf
Earnings Release
Open in viewerOpens in your device viewer
Organic growth rebounds in the third quarter : +8%
| Consolidated numbers in million Euros |
2009 | 2008 | % change | Evolution at constant exchange rates |
Evolution at constant scope and exchange rates |
|---|---|---|---|---|---|
| Net sales – 1st quarter | 109.0 | 103.2 | +5.6% | +7.3% | +3.3% |
| Net sales – 2nd quarter | 116.5 | 108.6 | +7.2% | +5.9% | +3.0% |
| Net sales - 3d quarter |
122.2 | 114.9 | +6.4% | +6.9% | +8.0% |
| Year-to-date 3d quarter |
347.7 | 326.7 | +6.4% | +6.7% | +4.8% |
Virbac's activity enjoyed an acceleration in organic growth during the third quarter, up to 8%. Such positive trend originates from one hand in the contribution from new products and in particular Effipro - parasiticide for companion animals - launched in June; and from another hand in the good performance of our product ranges in all geographical areas, translating into a noticeable increase of growth, including on the French market which had experienced a difficult first half.
On a year-to-date basis, the sales evolution is consequently keeping steady with a +6.7% growth at constant exchange rates (+6.6% at the end of june), with an acceleration of organic growth up to +4.8% (+3.1% end of June). These results are driven by the companion animals business in Europe and the United States and the food producing animals business in the emerging markets (India, South Africa, Latin American countries).
Overall, Virbac's growth at constant exchange rates in these two segments reaches 6.8% in companion animals and 10.2% in food producing animals (of which 4.2% organic growth and 6% due to the acquisitions made during 2008).
VIRBAC : Passionate about Animal Health NYSE Euronext - Compartiment B / Code ISIN : FR0000031577 / MNEMO : VIRP Corporate Finance : tél. 33 4 92 08 71 32 / Email : [email protected] website : www.virbac.com